Stockscreener 앱 받기
3.73
2.10%
-0.08
시간 외 거래:
3.73
Eledon Pharmaceuticals Inc 주식(ELDN)의 최신 뉴스
Can Eledon Pharmaceuticals Inc. stock recover from recent declineExponential wealth increase - jammulinksnews.com
Eledon Pharmaceuticals Advances Kidney Transplant Study with Tegoprubart - TipRanks
What drives Eledon Pharmaceuticals Inc. stock priceExceptional market performance - Autocar Professional
Is Eledon Pharmaceuticals Inc. a good long term investmentUnmatched market gains - Autocar Professional
Eledon Pharmaceuticals Inc. Stock Analysis and ForecastBreakout stock performance - jammulinksnews.com
What analysts say about Eledon Pharmaceuticals Inc. stockRobust financial gains - jammulinksnews.com
How Eledon Pharmaceuticals Inc. stock performs during market volatilityDefensive Stock Picks with Upside - Newser
Midday Stock Roundup: loanDepot Shoots Up 16% - Orange County Business Journal
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b - GlobeNewswire
Eledon to present updated kidney transplant study data at WTC By Investing.com - Investing.com South Africa
Eledon to present updated kidney transplant study data at WTC - Investing.com
New Phase 1b Data: Tegoprubart Shows Promise in Preventing Kidney Transplant Rejection30 Patient Update - Stock Titan
Why Eledon Pharmaceuticals Inc. stock attracts strong analyst attentionWeekly Double Return List - Newser
What makes Eledon Pharmaceuticals Inc. stock price move sharplyWealth Accumulation Stock List - Newser
Best Momentum Stocks to Buy for July 14th - Yahoo Finance
What is Lifesci Capital’s Estimate for ELDN Q2 Earnings? - Defense World
Cantor Fitzgerald reiterates Overweight rating on Eledon Pharmaceuticals stock By Investing.com - Investing.com Canada
Eledon Pharmaceuticals Rings the Closing Bell - Nasdaq
Extending Transplant Life Through Targeted Innovation - the-scientist.com
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | SEOVF Stock News - GuruFocus
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes - The Manila Times
Breakthrough: New Drug Collaboration Shows 5X Better Results in Type 1 Diabetes Cure Trial - Stock Titan
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) high institutional ownership speaks for itself as stock continues to impress, up 12% over last week - simplywall.st
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell Small Cap Comp Growth Index - MarketScreener
Eledon stock rating reiterated as Overweight by Cantor Fitzgerald - Investing.com Canada
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New Yo - GuruFocus
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City - Business Upturn
Eledon Pharmaceuticals: A Transplant Breakthrough on the Horizon? - AInvest
What is HC Wainwright’s Estimate for ELDN Q2 Earnings? - Defense World
What is HC Wainwright’s Estimate for ELDN Q1 Earnings? - Defense World
Eledon Pharmaceuticals (NASDAQ:ELDN) Rating Increased to Buy at HC Wainwright - Defense World
ELDN: HC Wainwright & Co. Sets New Price Target for Eledon Pharm - GuruFocus
H.C. Wainwright assumes coverage on Eledon stock with buy rating By Investing.com - Investing.com UK
3.32%
1.57%
자본화:
|
볼륨(24시간):